Evidence map›Paper›PMID 38967751›Full record

ReviewAdvances in experimental medicine and biology2024

Comparison of Non B-Ig and B-Ig.

Xiaojun Xu, Peter J Delves, Jing Huang, Wenwei Shao, Xiaoyan Qiu

Abstract readReviewComparative Study
PubMed Publisher
In one paragraph

Review in Advances in experimental medicine and biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xiaojun XuDepartment of Immunology, School of Basic Medical Sciences, Peking University, Beijing, China. xiaojunxu@bjmu.edu.cn.
Peter J DelvesDivision of Infection and Immunity, Department of Immunology, UCL (University College London), London, UK.
Jing HuangDepartment of Immunology, School of Basic Medical Sciences, Peking University, Beijing, China.
Wenwei ShaoAcademy of Medical Engineering and Translational Medicine, Tianjin University, Tianjin, China.
Xiaoyan QiuDepartment of Immunology, School of Basic Medical Sciences, Peking University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunoglobulin (Ig) has been widely acknowledged to be produced solely by B-lineage cells. However, growing evidence has demonstrated the expression of Ig in an array of cancer cells, as well as normal cells including epithelial cells, epidermal cells, mesangial cells, monocytes, and neutrophils. Ig has even been found to be expressed in non-B cells at immune-privileged sites such as neurons and spermatogenic cells. Despite these non-B cell-derived Igs (non-B-Igs) sharing the same symmetric structures with conventional Igs (B-Igs), further studies have revealed unique characteristics of non-B-Ig, such as restricted variable region and aberrant glycosylation. Moreover, non-B-Ig exhibits properties of promoting malignant behaviours of cancer cells, therefore it could be utilised in the clinic as a potential therapeutic biomarker or target. The elucidation of the generation and regulation of non-B-Ig will certainly broaden our understanding of immunology.

Indexed as

ImmunoglobulinsAnimalsB-LymphocytesGlycosylationHumansNeoplasmsImmunoglobulinsAntigen bindingClass switchingIgImmunoglobulin (Ig)Non-B cell-derived Ig (non-B-Ig)Post-translational modificationsSomatic hypermutationV(D)J recombination

Identifiers

PMID38967751

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.